Myriad Genetics, Inc.
(NASDAQ : MYGN)

( )
MYGN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -5.38%430.140.0%$5769.95m
BNTXBioNTech SE -5.53%333.480.0%$994.80m
NVAXNovavax, Inc. -3.55%248.1679.4%$950.95m
SNSSSunesis Pharmaceuticals, Inc. -0.46%8.650.7%$604.67m
AMGNAmgen, Inc. -0.67%213.611.4%$550.92m
GILDGilead Sciences, Inc. -0.70%71.191.0%$455.28m
REGNRegeneron Pharmaceuticals, Inc. -1.18%638.902.7%$418.56m
TECHBio-Techne Corp. 0.37%538.884.5%$356.85m
ILMNIllumina, Inc. -0.09%432.823.5%$356.73m
BIIBBiogen, Inc. -0.51%291.711.7%$309.48m
VRTXVertex Pharmaceuticals, Inc. -0.80%183.611.9%$245.25m
ISEEIVERIC bio, Inc. 0.86%16.370.0%$193.25m
DVAXDynavax Technologies Corp. 1.17%19.835.7%$156.65m
LIFEaTyr Pharma, Inc. -17.87%10.252.1%$156.36m
BGNEBeiGene Ltd. -1.53%379.521.3%$144.32m

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.